Furthermore, preclinical evaluations of therapeutic strategies targeting the HOXA10-AS/miR-99a-3p/ITGB5 axis, including antisense oligonucleotides or nanoparticle-based miRNA delivery systems, are warranted to assess their translational potential in improving glioblastoma treatment outcomes. The gene discussed is HOXA10; the disease is glioblastoma.